Phocas Financial Corp. trimmed its stake in shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 0.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,762,978 shares of the biotechnology company’s stock after selling 16,546 shares during the quarter. Progenics Pharmaceuticals accounts for about 1.2% of Phocas Financial Corp.’s holdings, making the stock its 15th largest position. Phocas Financial Corp. owned about 2.34% of Progenics Pharmaceuticals worth $14,174,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Clinton Group Inc. bought a new stake in shares of Progenics Pharmaceuticals during the 2nd quarter valued at $121,000. Jane Street Group LLC grew its position in Progenics Pharmaceuticals by 296.0% during the first quarter. Jane Street Group LLC now owns 48,685 shares of the biotechnology company’s stock worth $363,000 after buying an additional 36,391 shares in the last quarter. Trexquant Investment LP purchased a new position in Progenics Pharmaceuticals during the second quarter worth about $281,000. JPMorgan Chase & Co. grew its position in Progenics Pharmaceuticals by 268.7% during the first quarter. JPMorgan Chase & Co. now owns 326,562 shares of the biotechnology company’s stock worth $2,436,000 after buying an additional 237,992 shares in the last quarter. Finally, Employees Retirement System of Texas grew its position in Progenics Pharmaceuticals by 21.9% during the second quarter. Employees Retirement System of Texas now owns 139,000 shares of the biotechnology company’s stock worth $1,118,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 88.74% of the company’s stock.

Several research firms recently commented on PGNX. ValuEngine cut Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th. BidaskClub cut Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 5th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Needham & Company LLC cut Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and reduced their target price for the stock from $16.00 to $12.00 in a research report on Thursday, September 13th. Finally, Jefferies Financial Group restated a “buy” rating and set a $13.00 target price on shares of Progenics Pharmaceuticals in a research report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $11.69.

PGNX opened at $6.00 on Wednesday. Progenics Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.42. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.34 and a quick ratio of 6.34. The stock has a market capitalization of $423.14 million, a PE ratio of -6.67 and a beta of 2.40.

Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The company had revenue of $3.88 million for the quarter, compared to analysts’ expectations of $3.30 million. Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. equities research analysts expect that Progenics Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Progenics Pharmaceuticals Company Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Recommended Story: What does the Dow Jones Industrial Average (DJIA) measure?

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.